实用临床医学
實用臨床醫學
실용림상의학
Practical Clinical Medicine
2014年
6期
3-5
,共3页
抗栓治疗%调脂%阿托伐他汀%冠心病%血脂%炎性因子
抗栓治療%調脂%阿託伐他汀%冠心病%血脂%炎性因子
항전치료%조지%아탁벌타정%관심병%혈지%염성인자
antithrombotic treatment%lipid-lowering therapy%atorvastatin%coronary heart disease%blood lipid%inflammatory cytokines
目的：探讨调脂联合抗栓治疗冠心病的临床效果。方法将60例冠心病患者随机分为观察组和对照组，每组30例。对照组采用常规抗栓治疗(阿司匹林+氯吡格雷)，观察组在对照组治疗基础上采用他汀类降脂。比较2组的临床疗效、血脂水平、炎性因子水平及心血管不良事件发生情况。结果观察组总有效率显著高于对照组（90.0%比76.7%，P<0.05），而心血管不良事件发生率显著低于对照组（3.3%比13.3%，P<0.05）；2组治疗后血脂与炎性因子水平较治疗前均显著降低（P<0.05），观察组治疗后血脂水平与炎性因子水平较对照组降低更为显著（P<0.05）。结论调脂联合抗栓治疗冠心病能够降低炎性因子对心肌的损害，延缓动脉粥样硬化的进程，改善患者的预后。
目的：探討調脂聯閤抗栓治療冠心病的臨床效果。方法將60例冠心病患者隨機分為觀察組和對照組，每組30例。對照組採用常規抗栓治療(阿司匹林+氯吡格雷)，觀察組在對照組治療基礎上採用他汀類降脂。比較2組的臨床療效、血脂水平、炎性因子水平及心血管不良事件髮生情況。結果觀察組總有效率顯著高于對照組（90.0%比76.7%，P<0.05），而心血管不良事件髮生率顯著低于對照組（3.3%比13.3%，P<0.05）；2組治療後血脂與炎性因子水平較治療前均顯著降低（P<0.05），觀察組治療後血脂水平與炎性因子水平較對照組降低更為顯著（P<0.05）。結論調脂聯閤抗栓治療冠心病能夠降低炎性因子對心肌的損害，延緩動脈粥樣硬化的進程，改善患者的預後。
목적：탐토조지연합항전치료관심병적림상효과。방법장60례관심병환자수궤분위관찰조화대조조，매조30례。대조조채용상규항전치료(아사필림+록필격뢰)，관찰조재대조조치료기출상채용타정류강지。비교2조적림상료효、혈지수평、염성인자수평급심혈관불량사건발생정황。결과관찰조총유효솔현저고우대조조（90.0%비76.7%，P<0.05），이심혈관불량사건발생솔현저저우대조조（3.3%비13.3%，P<0.05）；2조치료후혈지여염성인자수평교치료전균현저강저（P<0.05），관찰조치료후혈지수평여염성인자수평교대조조강저경위현저（P<0.05）。결론조지연합항전치료관심병능구강저염성인자대심기적손해，연완동맥죽양경화적진정，개선환자적예후。
Objective To investigate the clinical effect of lipid-lowering therapy combined with antithrombotic treatment on coronary heart disease. Methods Sixty patients with coronary heart disease were randomly divided into two groups, with 30 patients in each group. The control group was given conventional antithrombotic treatment (aspirin plus clopidogrel). The observation group was given statins based on antithrombotic treatment. Clinical efficacy, blood lipid, inflammatory cytokines and cardiovascular adverse events were compared between the two groups. Results Compared with control group, lipid-lowering therapy increased the total effective rate(90.0% vs 76.7%,P<0.05),and decreased the incidence of cardiovascular adverse events(3.3% vs 13.3%,P<0.05). After treatment, levels of blood lipid and inflammatory cytokines significantly decreased in both group (P<0.05), and the decrease in observation group was more obvious than that in control group (P<0.05). Conclusion Lipid-lowering therapy combined with antithrombotic treatment can reduce inflammatory cytokine-induced myocardial damage, delay the progress of atherosclerosis and improve the prognosis in patients with coronary heart disease.
